论文部分内容阅读
吡柔比星(THP)是新一代半合成的蒽环类抗肿瘤抗生素,抗肿瘤谱广。为观察吡柔比星与其他抗肿瘤药联合治疗乳腺癌的效果,我院乳腺科将1999年8月至2006年12月期间收治的60例晚期乳腺癌患者分为CTF方案和CAF方案组,每组各30例,分别应用CTF与CAF方案,进行临床疗效和副作用对比,现报
Pirarubicin (THP) is a new generation of semi-synthetic anthracycline antitumor antibiotics, broad anti-tumor spectrum. To observe the effect of pirarubicin and other antineoplastic agents in the treatment of breast cancer, 60 patients with advanced breast cancer admitted from August 1999 to December 2006 were divided into CTF regimen and CAF regimen group. Each group of 30 cases, respectively, the application of CTF and CAF program, the clinical efficacy and side effects comparison, reported